GenFleet and BeiGene have signed a clinical trial collaboration and supply agreement to commence the P-Ib/II clinical evaluation of GFH009 (CDK9 inhibitor) + Brukinsa (BTK inhibitor) as a treatment of diffuse large B cell lymphoma (DLBCL)
Under the collaboration, GenFleet will initiate the P-Ib/II study to assess the safety & efficacy of the combination for treating patients with r/r DLBCL and BeiGene will supply Brukinsa for the same
Moreover, the company is investigating GFH009 for the treatment of peripheral T-cell lymphoma in China and acute myeloid leukemia across the US, the studies of which have been advanced to P-II
Ref: PR Newswire | Image: Sellas
Related News:- SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
